Table S3 - Cancer vs human network: solutions with an additional target.

Additional targets in boldface are those for which an experimental drug (other than the approved drugs listed in DrugBank) could be found in the literature.

Pathway	$Additional\ target$	Mimosine (#63)	Canaline (#81)	Lithium (#78)	Dorzolamide (#14)	Trichlormethiazide (#61)	Cerulenin (#62)	Orlistat (#65)	Droxidopa (#24)	Pentoxifylline (#50)	Zonisamide (#54)	Sulfasalazine (#48)	Carmustine (#17) - Fomepizole (#75)	Rosiglitazone (#7) - Gerulenin (#62)	Rosiglitazone (#7) - Orlistat (#65)	Carmustine (#17) - Cefdinir (#32) - Fomepizole (#75)	Disulfiram (#53) - Mimosine (#63) - Icatibant (#84)
Cysteine met.	Glutathione:cystine oxidoreductase												116			116	
Exchange	Bicarbonate exchange Phosphatidylcholine exchange Glycine exchange L-Cystine exchange L-Tyrosine exchange myo-Inositol exchange L-Arginine exchange		33	43	62	71			86		247		116	108	116		132
Fatty acid elong.	palmitoyl-CoA desaturase ^a						47	55									
Folate met. Lysine met.	methenyltetrahydrofolate cyclohydrolase ^b 2-Oxoadipate:lipoamide 2-oxidoreductase	29										138					
Nucleotides	guanylate kinase (GMP:ATP) adenylate kinase (d form) ribonucleoside-diphosphate reductase (GDP) ribonucleoside-diphosphate reductase (ADP)									62 62 62 60		100					
Oxidative Phosph.	inorganic diphosphatase											317					
R Group Synth.	R group to palmitate conversion R group artificial flux (C16:1)						44	52						89	97		
Transport	phosphatidylcholine transporter L-tyrosine transport						44	J2	86					108	116		
Tryptophan met.	2-oxoadipate shuttle 3-hydroxyacyl-CoA dehydratase ^c 3-hydroxyacyl-CoA dehydrogenase ^c											138 138 138					

a: inhibited by 5,6,7,8- tetrahydro-N⁵,N¹⁰- carbonylfolic acid [49];
b: inhibited by isomeric cis-octadecenoic acids [57];
c: inhibited by perfluorodecanoic acid [58];
c: inhibited by spiropentaneacetic acid [59].